MOTS-c vs NAD+: prices, identity and regulatory status (2026)
MOTS-c and NAD+ are different research compounds, not substitutes for each other: MOTS-c is a 16-amino-acid peptide (C101H152N28O22S2); NAD+ is a single compound (C21H27N7O14P2). Neither product has a current in-stock price right now. MOTS-c has no Drugs@FDA application.
Research use only. These are research-use-only listings sold for laboratory research, not prescription medicines and not for human use. PeptideTech does not compare effects or provide dosing information.
MOTS-c vs NAD+: current prices and packages
| Compared property | MOTS-c | NAD+ |
|---|---|---|
| Category | Longevity | Longevity |
| Compared package | 10mg | 500mg |
| Lowest current price | No current in-stock price | No current in-stock price |
| Price per labelled mg | — | — |
| Package sizes | 5mg, 10mg, 20mg, 40mg | 100mg, 250mg, 500mg, 750mg, 1000mg, 1500mg |
| Vendors with current prices | 0 | 0 |
| Form at this package | No listing | No listing |
| Stock | Out of stock | Out of stock |
Prices exclude shipping. The price per labelled mg is always given per mg, so different package sizes compare directly; it is shown only for single-compound vials and powders with a labelled mass. Blends, capsules, liquids and IU-labelled packages are compared by package total.
Identity, regulatory status and registered research
| Compared property | MOTS-c | NAD+ |
|---|---|---|
| Molecular formula | C101H152N28O22S2 | C21H27N7O14P2 |
| Molecular weight | 2174.6 g/mol | 663.4 g/mol |
| Sequence | H-Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg-OH (16 residues) | — |
| CAS Registry Number | 1627580-64-6 | 53-84-9 |
| Registered clinical trials | 1 (1 active) · Phase 2: 1 | 7 (3 active) · Phase 3: 1, Phase 2: 1, Early phase 1: 1 |
| Human intervention studies | None recorded | 1 |
| US regulatory status | No Drugs@FDA application (checked October 7, 2026) · Drugs@FDA search | No reviewed Drugs@FDA record |
Identity data: PubChem, FDA GSRS and EPA records; registry counts: ClinicalTrials.gov; status: Drugs@FDA. A matching name does not verify the contents of a supplier's lot.
Key human studies
MOTS-c
No human intervention study is recorded in the research library for this identity.
MOTS-c research profile →NAD+
- A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Frontiers in aging neuroscience, 2019
Studies are listed as records, newest first; they are not evidence that a research product is safe or effective.
Research-use listings for each compound
Research-use-only listings sold for laboratory research, not prescription medicines and not for human use.
MOTS-c
MOTS-c is a catalogue entry whose compound-specific reference review has not yet been completed.
No vendor has a current in-stock price for this package.
MOTS-c prices →Price history →NAD+
NAD+ is nicotinamide adenine dinucleotide, a nucleotide coenzyme rather than a peptide. A small human pilot examined plasma and urine metabolites during an intravenous infusion.
No vendor has a current in-stock price for this package.
NAD+ prices →Price history →Related comparisons
Questions
Automated price sources are scheduled daily; other sources are checked manually. Check the offer's last successful source timestamp. A code is shown when it is attached to an offer or affiliate link. The displayed price includes a discount only when that code is cart-verified and the discounted price is explicitly recorded; otherwise it is the vendor's listed price. Prices exclude shipping. Stock status is captured at the same time. Rankings are by displayed price, except that the labelled featured partner, LA Peptides, is pinned first; “Cheapest” always marks the lowest price. PeptideTech earns a commission when you buy through a link.
Full method →